ASH News Daily - Sunday, December 11, 2011 - (Page B-8)

Page B–8 ® ASH NewS DAily Sunday, December 11, 2011 CRTI Continues to Prepare Future Generations for Hematology Careers T he future of hematology lies in the hands of young, innovative hematologists, and to entrust the youth with such an important responsibility comes with it the need to fully equip them for the journey ahead. Not long ago, specialized training in clinical investigation was not available. In order to fill this void, ASH developed a unique train- 2012 CRTI Application Timeline Letter of Intent due: January 5 Application deadline: March 1 Notification: June 2012 Summer workshop dates: July 28 - August 3 Follow-up meeting: December 2012 Final class: May 2013 ing program known as the Clinical Research Training Institute (CRTI) in 2003. Established to increase the number and quality of clinical investigators in the field of hematology, CRTI has prepared hundreds of highly qualified leaders for the nation’s clinical research workforce. CRTI is a highly effective training model, bringing together promising fellows and early junior faculty in hematology, oncology, and bone marrow transplantation with renowned experts and mentors. Beverly S. Mitchell, MD, 2003 CRTI director and past ASH president, recalls mentoring a CRTI graduate who had not previously considered adding a foundation in laboratory research to his clinical trial experience but later went on to become an independent clinical investigator, receiving numerous careerdevelopment awards. “I have been extremely gratified by what CRTI has done to advance the ability of trainees and young faculty to carry out the very best clinical research in hematology.” The yearlong education and mentoring program begins with a weeklong summer workshop in La Jolla, CA, which focuses on the Attendees at the CRTI 2011 summer program. foundation, methodologies, and application of patient-oriented clinical research. Participants complete the training program with the knowledge and skills to conduct cuttingedge translational clinical research, and the benefits are innumerable. “It was one of the most amazing experiences,” 2011 CRTI participant Matthew S. Davids, MD, Harvard Medical School, said. “I walked away with a renewed sense of energy with respect to research.” A whirlwind of intellectual activity, the program caters to every step of the career path. During the August 2011 workshop, participants discussed topics such as methods of clinical trial design, job interviewing, and how to navigate institutional committees. »» CRTI Page B-31 Now Recruiting... A New Clinical Trial for Patients With Multicentric Castleman’s Disease About Multicentric Castleman’s Disease (MCD) MCD is a rare disorder characterized by abnormal noncancerous growths in the lymphatic tissues at multiple sites throughout the body and by systemic manifestations such as fever, night sweats, fatigue, anorexia, and wasting. Also known as giant lymph node hyperplasia or angiofollicular lymph node hyperplasia, MCD can also be misdiagnosed as malignant lymphoma. There is no currently approved treatment for MCD. Study Design 78 Total patients (2:1) Study Overview Ortho Biotech Oncology Research and Development, a unit of Centocor Research and Development, Inc., is conducting a pivotal registration study on MCD. Receive investigational treatment + BSC every 3 weeks Receive placebo + BSC every 3 weeks Primary Objective The primary objective of this study is to demonstrate that an investigational medicine plus best supportive care (BSC) is better than placebo plus BSC in patients with symptomatic MCD. About the Investigational Medicine The investigational medicine is a chimeric monoclonal antibody that blocks the function of the cytokine IL-6. Patients who do not respond to placebo + BSC may be switched to the investigational treatment + BSC The Castleman’s Study www.CastlemansResearch.com CNTO-MCD-ENG14 10 Nov 2009 The Castleman’s Study is being conducted in approximately 24 countries worldwide. As this trial presents a unique opportunity for patients with MCD, you may wish to consider referring your patients with this condition. To find out more, please visit www.CastlemansResearch.com 

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com